The long-term objective of this project is to develop a molecular-level understanding of the tissue selectivity of ligands that modulate the estrogen receptors (ERalpha and ERbeta). Drugs that target estrogen signaling pathways such as tamoxifen and raloxifene display antiestrogenic effects in certain tissues ans estrogenic effects in other tissues. Understanding the molecular basis of this tissue selectivity will be useful for designing safer and more effective-based therapeutics. The proposed experiments are designed to test the hypothesis that ER ligand pharmacology derives from the interplay of three parameters: ligand structure, receptor subtype (ERalpha and ERbeta), and the type of response element in the promoter of a given gene that is the site of regultion by the ER. The ER/AP-1 site is a response element where differential ligand activation profiles are observed for ERalpha and ERbeta.
The specific aim i s to map the regions of ERalpha and ERbeta that mediate this differential ligand activation. The second specific aim of the project is to probe the structural differences between raloxifene and tamoxifen to identify the chemical substructures of these drugs that correlate with the differences observed in ligand activation at an R/Ap-1 site. The ER/AP-1 assay that facilitated discovery of the differential ligand activation properties of ERalpha and ERbeta is an artificial cellular transcription assay that uses a test promoter driving transcription of a reporter gene. There is great interest now to ask whether endogenous in target tissues can be regulated in a similar way; i.e. in an ERbeta expressing tissue which genes are up-regulated by antiestrogens such as tamoxifen and raloxifene and down-regulated by estradiol? This question is addressed in specific aim 3 through experiments using differential gene expression array technology. The endogenous estrogen-regulated genes that are discovered with this approach will be characterized through experiments described in specific aim 4. In particular, the promoters of these genes will be analyzed to identify the type of response element that facilitates regulation through the ER.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK057574-04
Application #
6635245
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Program Officer
Margolis, Ronald N
Project Start
2000-05-01
Project End
2005-04-30
Budget Start
2003-05-01
Budget End
2005-04-30
Support Year
4
Fiscal Year
2003
Total Cost
$280,871
Indirect Cost
Name
University of California San Francisco
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Roepke, T A; Xue, C; Bosch, M A et al. (2008) Genes associated with membrane-initiated signaling of estrogen and energy homeostasis. Endocrinology 149:6113-24
Tobias, Sandra C; Qiu, Jian; Kelly, Martin J et al. (2006) Synthesis and biological evaluation of SERMs with potent nongenomic estrogenic activity. ChemMedChem 1:565-71
Qiu, Jian; Bosch, Martha A; Tobias, Sandra C et al. (2006) A G-protein-coupled estrogen receptor is involved in hypothalamic control of energy homeostasis. J Neurosci 26:5649-55
Clegg, Nicola J; Paruthiyil, Sreenivasan; Leitman, Dale C et al. (2005) Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands. J Med Chem 48:5989-6003
Shah, Nilesh; Scanlan, Thomas S (2004) Design and evaluation of novel nonsteroidal dissociating glucocorticoid receptor ligands. Bioorg Med Chem Lett 14:5199-203
Qiu, Jian; Bosch, Martha A; Tobias, Sandra C et al. (2003) Rapid signaling of estrogen in hypothalamic neurons involves a novel G-protein-coupled estrogen receptor that activates protein kinase C. J Neurosci 23:9529-40
Weatherman, R V; Chang, C-Y; Clegg, N J et al. (2002) Ligand-selective interactions of ER detected in living cells by fluorescence resonance energy transfer. Mol Endocrinol 16:487-96
Weatherman, R V; Clegg, N J; Scanlan, T S (2001) Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites. Chem Biol 8:427-36
Weatherman, R V; Scanlan, T S (2001) Unique protein determinants of the subtype-selective ligand responses of the estrogen receptors (ERalpha and ERbeta ) at AP-1 sites. J Biol Chem 276:3827-32
Weatherman, R V; Carroll, D C; Scanlan, T S (2001) Activity of a tamoxifen-raloxifene hybrid ligand for estrogen receptors at an AP-1 site. Bioorg Med Chem Lett 11:3129-31

Showing the most recent 10 out of 11 publications